BioSpace News Archive

Veracyte, Inc. announced new data showing that its Percepta Nasal Swab test accurately assesses lung cancer risk among current and former smokers with lung nodules, regardless of their smoking history burden and whether they are considered high risk for lung cancer based on U.S. Preventive Services Task Force screening criteria.

Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, announced the appointment of Laurie Stelzer as the Company’s Chief Financial Officer effective May 16, 2022.

NightHawk Biosciences, a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, provided strategic, financial, and operational updates for the first quarter ended March 31, 2022.

Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, is presenting preclinical proof-of-concept data from its second next-generation SPEAR T-cell targeting MAGE-A4, and novel tumor-infiltrating lymphocytes expressing IL-7 at the American Society of Gene & Cell Therapy annual meeting.

Petros Pharmaceuticals, Inc., a leading provider of therapeutics for men’s health, announced financial results for the first quarter ended March 31, 2022.

Aerovate Therapeutics, Inc. presents Phase 1 results at the American Thoracic Society International Conference in San Francisco.

ASC Therapeutics will provide a comprehensive review of IND-enabling studies of ASC618, a second-generation gene therapy for hemophilia A, at the 25th Annual Meeting of The American Society of Gene and Cell Therapy held May 16-19, 2022 in Washington, D.C. These studies were included in a filing to the U.S. Food and Drug Administration leading to IND clearance of ASC618.

ASC Therapeutics in partnership with the University of Massachusetts Medical School and the Clinic for Special Children, will present safety and efficacy results of a dual-function gene replacement vector therapy in murine and bovine models of classic Maple Syrup Urine Disease as a podium presentation on Tuesday, May 17 at the 25th Annual Meeting of The American Society of Gene and Cell Therapy held May 16-19, 2022 in Washington D.C.

Aytu BioPharma, Inc., a pharmaceutical company focused on developing and commercializing novel therapeutics, reported financial results for its fiscal 2022 third quarter, ended March 31, 2022 and outlined its key strategic priorities.

Homology Medicines, Inc., a genetic medicines company, announced financial results for the first quarter ended March 31, 2022, and highlighted recent accomplishments.